Iterum Therapeutics (ITRM)

[Johnstonj27]

Conference Call BOOM... finally get some info... better take questions.. what the hell was going on with COVID DRUG

https://www.stonkmoon.com/news/ITRM/1c7c2e1ccbae5de5ea3e74b6d590c3eb

ITRM -
0.59
+ 4.24%
(+0.17%)
extended hours
2021-11-05 07:00:00 ET (3 hours ago)
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results on November 12, 2021 Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its third quarter 2021 financial results before the open of the U.S. financial markets on Friday, November 12, 2021. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company’s financial results and provide an update on its business.

To access the call please dial 844-200-6205 (domestic) or 929-526-1599 (international) and refer to Access Code 442364. The audio webcast can be accessed under “Financials & Filings” in the Investors section of the Company’s website at www.iterumtx.com following the call.

About Iterum Therapeutics plc

Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is currently advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation. Sulopenem also has an IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit .

Forward-Looking Statements

This press release contains forward-looking statements. These forward-looking statements include, without limitation, statements regarding the development, therapeutic and market potential of sulopenem. In some cases, forward-looking statements can be identified by words such as “may,” “believes,” “intends,” “seeks,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “would,” “will,” “future,” “potential” or the negative of these or similar terms and phrases. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include all matters that are not historical facts. Actual future results may be materially different from what is expected due to factors largely outside the Company’s control, including uncertainties inherent in the initiation and conduct of clinical and non-clinical development, including any additional trials that may be conducted in response to the Complete Response Letter received by the Company in July 2021, availability and timing of data from such clinical and non-clinical development, changes in regulatory requirements or decisions of regulatory authorities, the timing or likelihood of regulatory filings and approvals, including the potential resubmission of a new drug application for sulopenem etzadroxil/probenecid, change